Statements (25)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:acquiredBy |
gptkb:Alfasigma
|
gptkbp:acquisitionYear |
2023
|
gptkbp:CEO |
gptkb:Jerry_Durso
|
gptkbp:country |
gptkb:United_States
|
gptkbp:focusesOn |
gptkb:nonalcoholic_steatohepatitis_(NASH)
gptkb:primary_biliary_cholangitis_(PBC) liver diseases |
gptkbp:founded |
2002
|
gptkbp:founder |
gptkb:Mark_Pruzanski
|
gptkbp:headquarters_location |
gptkb:Morristown,_New_Jersey,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label |
Intercept Pharmaceuticals
|
gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
gptkbp:notableProduct |
gptkb:obeticholic_acid
|
gptkbp:numberOfEmployees |
approximately 400
|
gptkbp:publiclyTraded |
yes
|
gptkbp:stockSymbol |
gptkb:ICPT
|
gptkbp:therapeuticArea |
gastroenterology
|
gptkbp:tradedOn |
gptkb:NASDAQ:_ICPT
|
gptkbp:website |
https://www.interceptpharma.com/
|
gptkbp:bfsParent |
gptkb:obeticholic_acid
gptkb:Frank_Verwiel gptkb:奥贝胆酸 |
gptkbp:bfsLayer |
6
|